Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixatimod - Zucero Therapeutics

Drug Profile

Pixatimod - Zucero Therapeutics

Alternative Names: PG-545

Latest Information Update: 14 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Progen Pharmaceuticals
  • Developer Bristol-Myers Squibb; Medigen Biotechnology Corporation; Progen Pharmaceuticals Limited; Zucero Therapeutics
  • Class Antineoplastics; Glycosaminoglycans; Oligosaccharides; Small molecules
  • Mechanism of Action Dendritic cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours
  • Preclinical Liver cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 13 Nov 2018 Preliminary efficacy, adverse events and pharmacodynamics data from a phase Ib trial in Solid tumours presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2018)
  • 24 Oct 2017 Phase-I clinical trials in Pancreatic cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
  • 24 Oct 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia (IV) (ACTRN12617001573347)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top